Luteolin reduces lipopolysaccharide-induced lethal toxicity and expression of proinflammatory molecules in mice

Anastasia Kotanidou, Angeliki Xagorari, Eleni Bagli, Panagiota Kitsanta, Theodore Fotsis, Andreas Papapetropoulos, Charis Roussos

Research output: Contribution to journalArticle

123 Scopus citations

Abstract

Luteolin is a flavonoid that has been shown to reduce proinflammatory molecule expression in vitro. In the present study, we have tested the ability of luteolin to inhibit lipopolysaccharide (LPS)-induced lethal toxicity and proinflammatory molecule expression in vivo. Mice receiving LPS (Salmonella enteriditis LPS, 32 mg/kg, intraperitoneally) exhibited high mortality with only 4.1% of the animals surviving seven days after the LPS challenge. On the contrary, mice that had received luteolin (0.2 mg/kg, intraperitoneally) before LPS showed an increased survival rate with 48% remaining alive on Day 7. To investigate the mechanism by which luteolin affords protection against LPS toxicity we measured intercellular adhesion molecule-1 (ICAM-1) and tumor necrosis factor-α (TNF-α) production in response to LPS in the presence or absence of luteolin pretreatment. Treatment of animals with LPS increased serum TNF-α levels in a time-dependent manner. The increase in peak serum TNF-α levels was sensitive to luteolin pretreatment. Luteolin pretreatment also reduced LPS-stimulated ICAM-1 expression in the liver and abolished leukocyte infiltration in the liver and lung. We conclude that luteolin protects against LPS-induced lethal toxicity, possibly by inhibiting proinflammatory molecule (TNF-α ICAM-1) expression in vivo and reducing leukocyte infiltration in tissues.

Original languageEnglish (US)
Pages (from-to)818-823
Number of pages6
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume165
Issue number6
DOIs
StatePublished - Mar 15 2002
Externally publishedYes

    Fingerprint

Keywords

  • Intercellular adhesion molecule
  • Lipopolysaccharide
  • Luteolin
  • Sepsis
  • Tumor necrosis factor-α

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this